PD-L1 Biomarker for Immunotherapy - Metastatic Breast Cancer Trial Talk

Research News

In March 2019, the FDA approved atezolizumab (Tecentriq®), the first PD-1/PD-L1 immune checkpoint inhibitor for metastatic triple-negative breast cancer, based on the IMpassion130 study. To qualify for atezolizumab immunotherapy, the cancer must also test positive for the PD-L1 protein.

This new approval brings immunotherapy to the landscape of MBC treatment. But there are still many questions. One important question is whether a PD-L1 test alone can adequately identify people who can benefit from atezolizumab and other PD-1/PD-L1 immune checkpoint inhibitors.

To get an understanding of the problem of using only PD-L1 positivity to identify people who may benefit from immune checkpoint inhibitors, and current research on how oncologists can identify people suited for immunotherapy, see the links below.

The Basics of PD-1 and PD-L1
First Immunotherapy and PD-L1 Test Approved for MBC
  • First Immunotherapy Approved for MBC  The April 2019 issue of Metastatic Trial Talk gives a good overview of the IMPassion130 study findings that led to the FDA approval of atezolizumab in 2019.
  • VENTANA PD-L1 SP142 Testing Assay  In breast cancer, atezolizumab is only approved for PD-L1 positive metastatic TNBC. To be prescribed atezolizumab you must get PD-L1 results using a specific lab test that the FDA approved, called the SP142 assay.
PD-L1 as the Single Biomarker for Immunotherapy: One Does Not Fit All
Find Trials

Last Modified on February 24, 2021



for past articles or specific information.